Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemiralisib in symptomatic COPD with prior exacerbations
NL-OMON45791Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Nemiralisib plus maintenance COPD therapy with Placebo plus maintenance COPD therapy (2 arms). Primary endpoint: Annualized rate of moderate and severe exacerbations. Started Jun 2018; status: active, not recruiting.
02
Drugs
nemiralisib
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON45791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45791.